StockData
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Decoy Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.17+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$622.40K
P/E (TTM)
–
Dividend yield
–

Decoy Therapeutics Inc. revenue by segment

By business segment

RevenueTTM Q2 26TTM Q1 26TTM Q4 25TTM Q3 25TTM Q2 25TTM Q1 25TTM Q4 24TTM Q2 19TTM Q1 19TTM Q4 18TTM Q3 18TTM Q2 18% of revenueYoY
Drug Development–––––––$0$0$0$0$0––
Consumer Operations–––––––$683.74K$764.54K$838.14K$957.90K$1.12M––
Operating incomeTTM Q2 26TTM Q1 26TTM Q4 25TTM Q3 25TTM Q2 25TTM Q1 25TTM Q4 24TTM Q2 19TTM Q1 19TTM Q4 18TTM Q3 18TTM Q2 18YoY
Reportable Segment-$14.84M-$13.18M-$12.61M-$5.07M-$5.18M-$5.68M-$5.73M–––––+186.6%
Drug Development–––––––-$1.08M-$7.22M-$11.89M-$15.94M-$19.76M–
Consumer Operations–––––––-$114.09K-$771.59K-$1.98M-$3.73M-$6.03M–

By product or service

RevenueTTM Q2 26TTM Q1 26TTM Q4 25TTM Q3 25TTM Q2 25TTM Q1 25TTM Q4 24TTM Q2 19TTM Q1 19TTM Q4 18TTM Q3 18TTM Q2 18% of revenueYoY
Net product revenue–––––––$676.14K$754.48K$826.52K$947.71K$1.11M––
Other revenue–––––––$7.61K$10.06K$11.63K$10.20K$12.85K––

By region

From the segment and revenue-disaggregation notes of Decoy Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.